Xsensio SA Secures $7M in Oversubscribed Series A to Enhance Biosensing Technology Deployment
Xsensio SA, a Swiss deep-tech firm at the forefront of continuous biochemical monitoring in near real-time, has successfully closed a $7 million oversubscribed Series A funding round. The financial boost comes primarily from WI Harper, a San Francisco-based venture capital firm, along with participation from Privilège Ventures, the European Innovation Council, and private investors across the United States, Europe, and Asia.
This influx of capital is a strategic move for Xsensio as it seeks to accelerate the development and clinical validation of its innovative biosensor platform known as Lab-on-Skin©. This wearable technology is designed to provide continuous, dynamic biochemical information that can significantly enhance clinical decision-making in hospital settings and beyond.
Esmeralda Megally, the CEO of Xsensio, emphasized the importance of this funding, stating, "This Series A is a crucial step toward implementing continuous biochemical monitoring in real-world clinical environments. For the first time, clinicians will have access to vital continuous biochemical data in real-time, information that previously was not available at the point of treatment. This can fundamentally improve how patients are monitored and treated."
Alongside the funding announcement, Xsensio revealed a long-term collaboration with Texas Instruments, a leader in the semiconductor technology sector. This partnership will lend vital expertise in CMOS integration, miniaturization, and mass production of biosensing systems, greatly enhancing Xsensio's ability to scale its technology for industrial applications. Adrian Ionescu, Xsensio’s technical director, stated, “Our collaboration with Texas Instruments significantly enhances our path toward advanced, scalable semiconductor technology. By combining our biosensing innovation with world-class semiconductor expertise, we’re building a platform designed for reliable and cost-effective clinical use.”
Wilson Wu, a partner at WI Harper, voiced strong support for Xsensio's mission, saying, “We believe that Xsensio is defining a new category of wearable biosensing technology. Given the tremendous advancements and market potential of the company, we are excited to lead this investment round.” Jaqueline Ruedin Rüsch, the chairperson of the board, noted that the shift to continuous biochemical monitoring signifies a major evolution from intermittent measurements to real-time insights, positioning Xsensio uniquely to lead this transformation.
Xsensio is dedicated to revolutionizing personalized healthcare through its groundbreaking Lab-on-Skin© platform, which continually delivers biochemical information in real-time. Born from leading academic research, the company works collaboratively with reference hospitals and industry partners to promote clinically meaningful biosensing innovations for patient care both inside and outside hospital environments. In recognition of its efforts, Xsensio was named one of the premier HealthTech companies of the year 2025 by TIME Magazine.
For more information about Xsensio, you can visit their official website at www.xsensio.com.
This influx of capital is a strategic move for Xsensio as it seeks to accelerate the development and clinical validation of its innovative biosensor platform known as Lab-on-Skin©. This wearable technology is designed to provide continuous, dynamic biochemical information that can significantly enhance clinical decision-making in hospital settings and beyond.
Esmeralda Megally, the CEO of Xsensio, emphasized the importance of this funding, stating, "This Series A is a crucial step toward implementing continuous biochemical monitoring in real-world clinical environments. For the first time, clinicians will have access to vital continuous biochemical data in real-time, information that previously was not available at the point of treatment. This can fundamentally improve how patients are monitored and treated."
Alongside the funding announcement, Xsensio revealed a long-term collaboration with Texas Instruments, a leader in the semiconductor technology sector. This partnership will lend vital expertise in CMOS integration, miniaturization, and mass production of biosensing systems, greatly enhancing Xsensio's ability to scale its technology for industrial applications. Adrian Ionescu, Xsensio’s technical director, stated, “Our collaboration with Texas Instruments significantly enhances our path toward advanced, scalable semiconductor technology. By combining our biosensing innovation with world-class semiconductor expertise, we’re building a platform designed for reliable and cost-effective clinical use.”
Wilson Wu, a partner at WI Harper, voiced strong support for Xsensio's mission, saying, “We believe that Xsensio is defining a new category of wearable biosensing technology. Given the tremendous advancements and market potential of the company, we are excited to lead this investment round.” Jaqueline Ruedin Rüsch, the chairperson of the board, noted that the shift to continuous biochemical monitoring signifies a major evolution from intermittent measurements to real-time insights, positioning Xsensio uniquely to lead this transformation.
Xsensio is dedicated to revolutionizing personalized healthcare through its groundbreaking Lab-on-Skin© platform, which continually delivers biochemical information in real-time. Born from leading academic research, the company works collaboratively with reference hospitals and industry partners to promote clinically meaningful biosensing innovations for patient care both inside and outside hospital environments. In recognition of its efforts, Xsensio was named one of the premier HealthTech companies of the year 2025 by TIME Magazine.
For more information about Xsensio, you can visit their official website at www.xsensio.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.